News >

Novel Triplets, Potent Single Agents Emerge Across Myeloma Spectrum

Caroline Seymour
Published: Friday, Jun 07, 2019

Yubin Kang, MD

Yubin Kang, MD

Several triplet and now quadruplet regimens have demonstrated utility in patients with transplant-eligible and -ineligible multiple myeloma, and these advances are being echoed in the relapsed/refractory setting with monotherapies, such as selinexor and venetoclax (Venclexta).

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid) and dexamethasone (KRd) is one such regimen poised to enter the paradigm after demonstrating superior objective response rates, irrespective of risk status, and attainment of minimal residual disease negativity compared with carfilzomib and cyclophosphamide/dexamethasone in patients with newly diagnosed disease.

In the relapsed/refractory setting, selinexor and venetoclax have shown potent activity in heavily pretreated and high-risk patient populations, respectively. Pending confirmatory data from the phase III BOSTON trial, which is anticipated to read out by July 6, 2019, the FDA will make a decision on approving selinexor.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x